Research Paper Volume 12, Issue 5 pp 4641—4659

Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models

class="figure-viewer-img"

Figure 2. MTS assay of cells treated with different concentration of SLAB51 (left). MTS assay of cells treated with 35 μM 6-OHDA and 35 μM 6-OHDA and SLAB51 0.1mg/ml (right). Data are mean ± SE of three different experiments run in quadruplicate (n=3). *** p< 0.0005 vs Ctr; +++ p< 0.0005 vs 6-OHDA.